Delayed/sustained release of macromolecules

• US 4,959,217 A
• Filed: 05/22/1986
• Issued: 09/25/1990
• Est. Priority Date: 05/22/1986
• Status: Expired due to Fees

• Current Assignee: Syntec Incorporated (Atos SE)
• Original Assignee: Syntec Incorporated (Atos SE)
• Inventors: Domb, Abraham, Sanders, Lynda M.
• Primary Examiner(s): Page, Thurman K.
• Application Number:
  US06/866,042
• Time in Patent Office: 1,587 Days
• Field of Search: 514/800, 424/473, 424/425, 424/427, 424/486, 424/433, 424/436, 424/487
• US Class Current: 424/473
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes

Abstract

This invention concerns novel, delayed/sustained release devices and compositions, including methods of their manufacture and use. The compositions include macromolecules, particularly polypeptide pharmaceuticals, and an initially partially-hydrated, non-biodegradable, hydrogel rate-limiting membrane.

Claims

1. A drug delivery device for the controlled administration of a macromolecular drug, said device comprising:

(a) a pharmaceutically acceptable carrier;

(b) a macromolecular drug having a molecular weight greater than about 1,000 mixed with said carrier; and

(c) an initially partially-hydrated, non-biodegradable, hydrogel rate-limiting membrane, wherein said membrane;

(i) comprises a homopolymer or a copolymer material surrounding said carrier and drug, and

(ii) has an initial water content such that it is substantially non-permeable to said macromolecular drug.

2. The drug delivery device of claim 1 wherein said carrier is saturated with said drug and wherein an excess of said drug in a solid state is disposed in contact with said drug-saturated carrier.

3. The drug delivery device of claim 1 wherein said membrane is initially hydrated to such an extent that it is structurally manipulable.

4. The drug delivery device of claim 1 wherein said membrane comprises a crosslinked HEMA homopolymer.

5. The drug delivery device of claim 1, which is a monolithic reservoir.

6. The drug delivery device of claim 1 wherein said carrier is silicone oil.

8. The drug delivery device of claim 1 useful as an ocular insert.

9. The drug delivery device of claim 1 wherein said membrane is selected from the group of crosslinked and non-crosslinked homopolymers or copolymers consisting of:

HEMA, GMA, HEMA/GMA, HEMA/MMA, GMA/MMA, and HEMA/GMA/MMA.

10. The drug delivery device of claim 9, which is a reservoir, wherein said carrier is silicone oil.

11. The drug delivery device of claim 9 useful as an ocular insert.

12. The drug delivery device of claim 1 wherein said macromolecular drug comprises a hydrophilic polypeptide.

13. The drug delivery device of claim 1 wherein said macromolecular drug comprises a luteinizing hormone-releasing hormone analog or a pharmaceutically acceptable salt thereof.

14. The drug delivery device of claim 13 wherein said carrier is saturated with said drug and wherein an excess of said drug in a solid state is disposed in contact with said drug-saturated carrier.

15. The drug delivery device of claim 13 wherein said analog is a luteinizing hormone-releasing hormone agonist or a pharmaceutically acceptable salt thereof.

16. The drug delivery device of claim 13 wherein said analog is a luteinizing hormone-releasing hormone antagonist or a pharmaceutically acceptable salt thereof.

17. The drug delivery device of claim 13 wherein said analog is nafarelin acetate.

18. The drug delivery device of claim 17 wherein said membrane is initially hydrated to a water content of less than about 30%.

19. The drug delivery device of claim 17 wherein said membrane is hydratable to an equilibrium water content of about 35%-45%.

20. The drug delivery device of claim 17 wherein said membrane is hydratable to an equilibrium water content of about 39%.

21. The drug delivery device of claim 13 wherein said analog is aza-Gly¹⁰ nafarelin acetate.

22. The drug delivery device of claim 1 wherein said membrane is hydratable to an equilibrium water content such that it limits the diffusion of said macromolecular drug from said carrier to a delivery environment.

23. The drug delivery device of claim 1 wherein said macromolecular drug is selected from the group consisting of:

hormonally active polypeptides, mammalian growth hormones, mammalian growth hormone-releasing hormones, and polypeptides having thymosin activity.

7. A device for the delayed/sustained release of a compound, said device comprising:

(a) a macromolecular compound having a molecular weight greater than about 1,000;

(b) a carrier having said macromolecular compound mixed therewith; and

(c) an initially partially-hydrated, non-biodegradable, hydrogel rate-limiting membrane, wherein said membrane;

(i) comprises a homopolymer or a copolymer material surrounding said carrier and macromolecular compound,

(ii) is substantially non-permeable to said macromolecular compound when in said initially partially-hydrated state, and

(iii) is hydratable, when placed in a delivery environment, to become permeable to said macromolecular compound.

48. The device of claim 7 wherein said membrane is hydratable to an equilibrium water content at which it limits the diffusion of said macromolecular compound from said carrier to a delivery environment.

24. A pharmaceutical formulation for controlled release of a luteinizing hormone-releasing hormone analog, said formulation comprising:

(a) a pharmaceutically acceptable carrier;

(b) an effective amount of at least one luteinizing hormone-releasing hormone analog or a pharmaceutically acceptable salt thereof disposed in contact with said carrier; and

(c) an initially partially-hydrated, non-biodegradable, hydrogel rate-limiting membrane surrounding said carrier, said membrane being;

(i) initially hydrated to a water content of about 5% to less than about 30% by weight before placement in a delivery environment, and

(ii) hydratable to an equilibrium water content of about 30% to about 80% by weight when in a delivery environment.

25. The formulation of claim 24 wherein said analog is a luteinizing hormone-releasing hormone agonist.

26. The formulation of claim 24 wherein said analog is a luteinizing hormone-releasing hormone antagonist.

27. The formulation of claim 24 wherein said analog is nafarelin acetate.

28. The formulation of claim 25 wherein said analog is a nonapeptide or a decapeptide having the formula:

space="preserve" listing-type="equation">(pyro)Glu-His-V-Ser-W-X-Y-Arg-Pro-Z

or a pharmaceutically acceptable salt thereof, wherein;

V is tryptophyl, phenylalanyl or 3-(1-naphthyl)-L-alanyl;

W is tyrosyl, phenylalanyl or 3-(1-pentafluorophenyl)-L-alanyl;

X is a D-amino acid residue having the formula;

##STR5## wherein R is;

(a) a carbocyclic aryl-containing radical selected from the group consisting of naphthyl, anthryl, fluorenyl, phenylanthryl, biphenylyl, benzhydryl and phenyl substituted with three or more straight chain lower alkyl groups;

or

(b) a saturated carbocyclic radical selected from the group consisting of cyclohexyl substituted with three or more straight chain lower alkyl groups, perhydronaphthyl, perhydrobiphenylyl, perhydro-2,2-diphenylmethyl and adamantyl;

Y is leucyl, isoluecyl, nor-leucyl or N-methyl-leucyl; and

Z is glycinamide or --NH--R₁,

wherein R₁ is lower alkyl, cycloalkyl, fluoro lower alkyl or has the formula;

##STR6## wherein R₂ is hydrogen or lower alkyl.

29. The formulation of claim 28 wherein:

V is tryptophyl or phenylalanyl;

W is tyrosyl;

X is 3-(2-naphthyl)-D-alanyl or 3-(2,3,6-trimethylphenyl)-D-alanyl;

I is leucyl or N-methyl-leucyl; and

Z is glycinamide, NHEt or has the formula;

##STR7##

30. The formulation of claim 24 wherein said luteinizing hormone-releasing hormone analog is (pyro)Glu-His-Trp-Ser-Tyr-3-(naphthyl)-D-alanyl-Leu-Arg-Pro-Gly-NH₂ or a pharmaceutically acceptable salt thereof.

31. The formulation of claim 30 comprising an ocular insert containing 2.0 mg of said luteinizing hormone-releasing hormone analog suspended in 0.2 ml of a silicone oil carrier, wherein said membrane is a 0.5% EGDMA-crosslinked HEMA homopolymer having an initial water content less than or equal to 29%.

32. The formulation of claim 24 wherein said luteinizing hormone-releasing hormone analog is (pyro)Glu-His-Trp-Ser-Tyr-3-(naphthyl)-D-alanyl-Leu-Arg-Pro-aza-Gly-NH.sub.2 or a pharmaceutically acceptable salt thereof.

33. The formulation of claim 32 comprising a reservoir device containing 30.0 mg of said luteinizing hormone-releasing hormone analog suspended in 0.3 ml of a silicone oil carrier, wherein said membrane is a 0.5% EGDMA-crosslinked HEMA homopolymer having an initial water content less than or equal to 29%.

34. The formulation of claim 24, wherein the luteinizing hormone-releasing hormone is an analog of natural luteinizing hormone-releasing hormone, in which the 6-position residue is changed from Gly to a D-amino acid.

35. A formulation according to claim 34, wherein the D-amino acid is D-Ala, D-Lue, D-Phe or D-Trp.

36. A formulation according to claim 34, wherein the D amino acid is D-Leu.

37. A formulation according to claim 34, wherein the D amino acid is D-Trp.

38. The formulation according to claim 24, wherein said carrier is selected from the group:

(a) aqueous systems;

(b) solvents;

(c) solid substrates;

(d) unpolymerized monomers or comonomers;

(e) xerogels;

(f) partially hydrated hydrogels; and

(g) fully hydrated hydrogels.

39. The formulation according to claim 38, wherein said carrier is silicone oil.

42. The formulation of claim 24 wherein said hydrogel comprises a copolymer of:

(a) 50-100 mole % HEMA;

(b) 0-50 mole % MMA;

(c) 0-10 mole % crosslinking agent; and

(d) 0.01-5 mole % polymerization initiator.

43. The formulation of claim 24 wherein said hydrogel comprises a copolymer of:

(a) 75-100 mole % HEMA;

(b) 0-25 mole % MMA;

(c) 0-5 mole % crosslinking agent; and

(d) 0.01-2 mole % polymerization initiator.

44. The formulation of claim 24 wherein said membrane is selected from the group of crosslinked and non-crosslinked homopolymers or copolymers consisting of:

HEMA, GMA, HEMA/GMA, HEMA/MMA, GMA/MMA, and HEMA/GMA/MMA.

45. The formulation according to claim 24, wherein said membrane comprises a 0.32% EGDMA-crosslinked homopolymer of HEMA.

46. The formulation according to claim 24, which is a reservoir device.

47. The formulation according to claim 24 useful as an ocular insert.

40. A drug delivery device for the controlled administration of a macromolecular drug, said device comprising:

(a) a pharmaceutically acceptable carrier;

(b) a macromolecular drug having a molecular weight greater than about 1,000 disposed in contact with said carrier; and

(c) an initially partially-hydrated, non-biodegradable, hydrogel rate-limiting membrane, wherein said membrane;

(i) comprises a homopolymer or a copolymer material surrounding said carrier, and

(ii) has an initial water content such that it is structurally manipulable.

41. The drug delivery device of claim 40 wherein said macromolecular drug is selected from the group consisting of:

hormonally active polypeptides, mammalian growth hormones, mammalian growth hormone-releasing hormones, and polypeptides having thymosin activity.